Intercept Pharmaceuticals (NASDAQ:ICPT) Target Lowered by Stifel Nicolaus to $51.00

0
35
Financial data analysis graph showing stock market trends on a trading board. Horizontal composition with copy space and selective focus.

Intercept Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Intercept Pharmaceuticals stock Target Lowered by   Stifel Nicolaus on 6/29/2020. In a note to investors, the firm issued a new target price of $51.00. The analysts previously had $100.00 target price. Stifel Nicolaus’s price target would indicate a potential upside of 9.21% from the stock’s previous close.

Shares of Intercept Pharmaceuticals traded down -$30.79 on Monday, reaching $46.70. 167 shares of the stock traded hands, compared to its average volume of 729897. Shares of were trading at $46.70 on Monday. The firm’s 50 day moving average is $$80.20 and its 200 day moving average is $84.66.Intercept Pharmaceuticals  has a 12 month low of $44.50 and a 12 month high of $125.00. While on yearly highs and lows, Intercept Pharmaceuticals today has traded high as $50.00 and has touched $44.50 on the downward trend.

Intercept Pharmaceuticals Earnings and What to expect: 

Intercept Pharmaceuticals last released its quarterly earnings results on May 11th, 2020. The biopharmaceutical company reported ($2.86) EPS for the quarter, beating the consensus estimate of ($2.94) by $0.08. The business had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $69.67 million. Its quarterly revenue was up 39.1% on a year-over-year basis. Intercept Pharmaceuticals has generated ($10.89) earnings per share over the last year. Intercept Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 5th, 2020 based off prior year’s report dates.

Earnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($11.30) to ($8.10) per share. The P/E ratio of Intercept Pharmaceuticals is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Intercept Pharmaceuticals is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Intercept Pharmaceuticals has a P/B Ratio of 29.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 23.70%
  • On 5/13/2020 Director Paolo Fundaro Sell 595,578 at average share price of $84.60 which equates to $50,385,898.80 in money value.
  • On 4/27/2020 EVP Christian Weyer Sell 181 at average price of  $85.95 with total value of : Not Data Available
  • On 4/9/2020 Insider David A Ford Sell 58 at average price of  $70.00 with total value of : $4,060.00
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Intercept Pharmaceuticals

  • 6/29/2020 – Intercept Pharmaceuticals was downgraded by analysts at Raymond James from an “outperform” rating to a “market perform” rating.
  • 6/29/2020 – Intercept Pharmaceuticals was downgraded by analysts at Goldman Sachs Group Inc from a “buy” rating to a “neutral” rating. They now have a $60.00 price target on the stock, down previously from $150.00.
  • 6/29/2020 – Intercept Pharmaceuticals was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating. They now have a $52.00 price target on the stock, down previously from $107.00.
  • 6/29/2020 – Intercept Pharmaceuticals was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $55.00 price target on the stock, down previously from $117.00.
  • See More Analyst Rating at: RATING

Other rating updates by Stifel Nicolaus: 

  • 6/29/2020 – is now covered by analysts at Stifel Nicolaus. They set a “buy” rating on the stock.
  • 6/29/2020 – Archrock is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $8.00 price target on the stock.
  • 6/29/2020 – Petro Matad was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating.
  • 6/29/2020 – ZoomInfo Technologies is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $60.00 price target on the stock.
  • See More Analyst Rating at: RATING

Intercept Pharmaceuticals (NASDAQ:ICPT) Moving Average Technical Analysis

5 day Moving Average is $$72.77 And 5 day price change is -$34.08 (-42.19%)  with average volume for 5 day average is 2,610,160. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $76.55 and 20 day price change is -$26.84 (-36.50%) and average 20 day moving volume is 1,086,190. 50 day moving average is $80.20  and 50 day price change is -$34.57 ( -42.54%)  and with average volume for 50 days is : 877,892. 200 day moving average is $84.66  and 200 day price change is -$21.37 (-31.39%)  and with average volume for 200 days is : 672,000.

See More Analyst Rating at: RATING